Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE ENANTHATE versus TESTRED.
TESTOSTERONE ENANTHATE vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
50-400 mg intramuscularly every 2-4 weeks
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category D/X
Category C
Androgen
Androgen